Clinical Trials
12 trialsNCT04072952 2026-04-15
mBC
Arvinas Inc.
Phase 1/2 Completed
NCT05039177 2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2 Completed
NCT03844997 2025-05-31
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT04494958 2025-03-24
PALBOBIN
Fundacion Oncosur
Phase 1/2 Completed
NCT03774472 2025-02-17
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03560531 2024-08-09
A Study of ZN-c5 in Subjects With Breast Cancer
Zeno Alpha Inc.
Phase 1/2 Completed
NCT02101034 2023-12-21
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
Washington University School of Medicine
Phase 1/2 Completed
NCT03054363 2023-11-13
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
University of Colorado, Denver
Phase 1/2 Completed
NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
NCT02448771 2022-10-24
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT03965845 2022-09-19
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Completed
NCT02871791 2022-08-29
Palbociclib With Everolimus + Exemestane In BC
Dana-Farber Cancer Institute
Phase 1/2 Completed